Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Biological Phenomena, Cell Phenomena, and Immunity (2)
- Chemicals and Drugs (2)
- Medical Sciences (2)
- Medicinal Chemistry and Pharmaceutics (2)
- Toxicology (2)
-
- Biochemistry (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Cellular and Molecular Physiology (1)
- Chemical Actions and Uses (1)
- Chemical and Pharmacologic Phenomena (1)
- Genetic Processes (1)
- Medical Cell Biology (1)
- Medical Specialties (1)
- Medical Toxicology (1)
- Molecular Biology (1)
- Oncology (1)
- Pharmaceutical Preparations (1)
- Physiological Processes (1)
- Physiology (1)
- Keyword
-
- Cytoprotection (2)
- RRNA maturation (2)
- 3T3 Cells (1)
- 9-aminoacrodine (1)
- Animals (1)
-
- Antineoplastic Agents (1)
- Biological (1)
- CRISPR-Cas Systems (1)
- Cancer treatment (1)
- Cell Cycle (1)
- Chemotherapeutic agents (1)
- Cyclotherapy (1)
- Cytotoxins (1)
- DNA Damage (1)
- Drug Resistance (1)
- Drug Resistance, Neoplasm (1)
- Gene Editing (1)
- Gene Targeting (1)
- Mice (1)
- Models (1)
- Models, Biological (1)
- Neoplasm (1)
- Nuclear Proteins (1)
- P53 (1)
- Post-Transcriptional (1)
- Protein Biosynthesis (1)
- RBG inhibition (1)
- RNA Processing (1)
- RNA Processing, Post-Transcriptional (1)
- RNA-Binding Proteins (1)
Articles 1 - 3 of 3
Full-Text Articles in Cancer Biology
Targeting Ribosome Assembly Factors Selectively Protects P53 Positive Cells From Chemotherapeutic Agents, Russell T. Sapio, Anastasiya Nezdyur, Matthew Krevetski, Leonid Anikin, Vincent J. Manna, N. Minkovsky, Dimitri G Pestov
Targeting Ribosome Assembly Factors Selectively Protects P53 Positive Cells From Chemotherapeutic Agents, Russell T. Sapio, Anastasiya Nezdyur, Matthew Krevetski, Leonid Anikin, Vincent J. Manna, N. Minkovsky, Dimitri G Pestov
Rowan-Virtua School of Osteopathic Medicine Faculty Scholarship
Many chemotherapeutic agents act in a nondiscriminatory fashion, targeting both cancerous and noncancerous cells in Sphase and Mphase. One approach to reduce the toxic side effects in normal tissue is to exploit the differences in p53 functionality between cancerous and noncancerous cells. For example, activating p53 signaling by nongenotoxic means can transiently arrest noncancerous p53 positive cells in G1 phase and protect them from the cytotoxic effects of chemotherapeutic drugs. However, since most cancerous cells have faulty p53 signaling, they will proceed to cycle, and continue to be affected by the drug. In this study we asked if this G1‐phase …
9-Aminoacridine Inhibits Ribosome Biogenesis And Synergizes With Cytotoxic Drugs To Induce Selective Killing Of P53-Deficient Cells, Leonid Anikin, Dimitri G Pestov
9-Aminoacridine Inhibits Ribosome Biogenesis And Synergizes With Cytotoxic Drugs To Induce Selective Killing Of P53-Deficient Cells, Leonid Anikin, Dimitri G Pestov
Rowan-Virtua School of Osteopathic Medicine Faculty Scholarship
Common cancer treatments target rapidly dividing cells and do not discriminate between cancer and normal host cells. One approach to mitigating negative side‐effects of cancer treatment is to temporarily arrest cell cycle progression and thus protect normal cells during cytotoxic treatments, a concept called cyclotherapy. We recently proposed that transient inhibition of post‐transcriptional steps of ribosome biogenesis (RBG) can be used to selectively arrest p53‐positive host cells and not p53‐null cancer cells. In this study, we investigated whether cytoprotective RBG inhibition can be achieved through small molecule treatment.
Inhibition Of Post-Transcriptional Steps In Ribosome Biogenesis Confers Cytoprotection Against Chemotherapeutic Agents In A P53-Dependent Manner, Russell T Sapio, Anastasiya N Nezdyur, Matthew Krevetski, Leonid Anikin, Vincent J Manna, Natalie Minkovsky, Dimitri G Pestov
Inhibition Of Post-Transcriptional Steps In Ribosome Biogenesis Confers Cytoprotection Against Chemotherapeutic Agents In A P53-Dependent Manner, Russell T Sapio, Anastasiya N Nezdyur, Matthew Krevetski, Leonid Anikin, Vincent J Manna, Natalie Minkovsky, Dimitri G Pestov
Rowan-Virtua School of Osteopathic Medicine Faculty Scholarship
The p53-mediated nucleolar stress response associated with inhibition of ribosomal RNA transcription was previously shown to potentiate killing of tumor cells. Here, we asked whether targeting of ribosome biogenesis can be used as the basis for selective p53-dependent cytoprotection of nonmalignant cells. Temporary functional inactivation of the 60S ribosome assembly factor Bop1 in a 3T3 cell model markedly increased cell recovery after exposure to camptothecin or methotrexate. This was due, at least in part, to reversible pausing of the cell cycle preventing S phase associated DNA damage. Similar cytoprotective effects were observed after transient shRNA-mediated silencing of Rps19, but not …